Graphene Nanotubes Revolutionize Protective Film Technology: Ultrathin, Permanently Conductive PSA

A novel conductive PSA exhibits remarkable transparency and maintains stable electrical conductivity throughout its lifespan.. Graphene nanotubes inside adhesives make it possible to reduce the number of layers, improving cost-efficiency of processing. The new set of properties enabled by nanotubes expands PSA’s standard range of applications, encompassing optical films, flexible displays, and more.

The global market for conductive pressure-sensitive adhesives (PSAs) is forecast to reach $12.5 billion by 2025, driven by wide-ranging applications. To keep growing, the industry has always been on the lookout for solutions for anti-static PSA, without drawbacks such as degradation of conductivity over time, low transparency, or limited flexibility.

OCSiAl’s exceptional graphene nanotube -based solution addresses these issues, ushering in a new era of silicone PSA technology. The user-friendly nanotube dispersion TUBALLTM MATRIX 617 results in excellent electrical conductivity combined with more than 90% transparency in a wide range of peeling-strength PSA films.

The nanotube concentrate can be seamlessly integrated into silicone PSA resins without altering standard mixing processes or equipment. “The recently developed product is a concentrate based on a user-friendly reactive silicone polymer and pre-dispersed TUBALL™ graphene nanotubes specifically designed for silicone PSA systems. It offers an extremely fine quality of nanotube dispersion and is easier to handle in specific applications, notably in a low solid-content systems,” said Ekaterina Gorbunova, Development and Support Leader for Elastomers and Vice President at OCSiAl Group.

Just 0.2% TUBALL™ MATRIX 617 ensures uniform dispersion of conductive particles inside PSA film. This results in a stable surface resistivity of less than 107 Ohm/sq, even after multiple peelings and exposure to high temperatures, which makes it possible to meet strict requirements for stable touch screen operations. In comparison, traditional PSA on conventional polymer primer can only achieve surface resistivity of 1010Ohm/sq, because above this level, it tends to become unstable over time.

The newly developed, permanently conductive silicone PSA formulations reduce the number of layers needed, eliminate the requirement for a primer, and improve cost-efficiency. The outcome is a new generation of fine, flexible, transparent, sensitive films suitable for applications in high demand in electronics, medical devices, the automotive industry, and packaging.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”